MNOV 最新10-Q变化
将 MNOV 最新的定期申报(10-K/10-Q)与上一份同类型申报逐章节对比:每个章节新增/删除的段落数与原文摘录。全部为确定性文本对比——无相似度评分、无方向判断、非投资建议。
对比:10-Q · 2026-05-14 与上一份 10-Q · 2025-11-12
| 章节 | 结果 | 新增 | 删除 | 微调 | 未变 |
|---|---|---|---|---|---|
| 管理层讨论与分析 | 文字有新增/删除 | +9 | −13 | ~13 | 13 |
| 控制与程序 | 无段落级文字变化 | 0 | 0 | 0 | 4 |
| 法律诉讼 | 文字有新增/删除 | 0 | 0 | ~1 | 0 |
| 风险因素 | 文字有新增/删除 | 0 | 0 | ~1 | 0 |
| 其他信息 | 文字有新增/删除 | 0 | 0 | ~1 | 1 |
计数单位为段落;"新增/删除"指相对上一份文件新增/删除的文字,不含方向或好坏判断。
未列出(无法可靠提取或缺失):市场风险(第3项)
代表性摘录
每个章节最多 5 条、每条约 300 字符的原文摘录,直接来自两份 SEC 文件。
管理层讨论与分析
相对上期新增的文字 · 来源:10-Q · 2026-05-14
Interest income was $0.3 million for both the three months ended March 31, 2026 and 2025. The income was relatively the same quarter over quarter.
Net cash used in operating activities during the three months ended March 31, 2026 was $3.5 million compared to $3.8 million during the same period in 2025. The $0.3 million change is primarily related to the changes in operating assets and liabilities for those periods.
As of March 31, 2026, we had available cash and cash equivalents of $27.3 million and working capital of $25.1 million. As of the date of this report, we believe we have working capital sufficient to fund operations at least through May 2027. However, we cannot provide assurance that these capital r…
In August 2019, we entered into an at the market issuance sales agreement, which was amended on August 26, 2022 (as amended, the ATM Agreement) with B. Riley FBR, Inc. (B. Riley FBR) pursuant to which we may sell common stock through B. Riley FBR from time to time up to an aggregate offering price o…
No shares of common stock were sold under the ATM Agreement in the three months ended March 31, 2026 and 2025.
相对上期删除的文字 · 来源:10-Q · 2025-11-12
Interest income was $0.3 million and $0.4 million for the three months ended September 30, 2025 and 2024, respectively. The decrease of $0.1 million was primarily driven by a decrease in our cash balance generating interest. Interest income consists of interest earned on our cash and cash equivalent…
Comparison of the nine months ended September 30, 2025 and 2024
Revenues were $0.3 million and $0.0 million for the nine months ended September 30, 2025 and 2024, respectively. The increase of $0.3 million was due to revenue recognized under our agreement with Mayo, which was entered into in December 2024 and which began enrolling patients in March 2025, and und…
Cost of services were $0.2 million and $0.0 million for the nine months ended September 30, 2025 and 2024, respectively. The increase of $0.2 million was due to the costs incurred for services provided related to the Mayo agreement.
Research, development and patents expenses were $5.6 million and $5.3 for the nine months ended September 30, 2025 and 2024, respectively. The increase of $0.3 million was primarily driven by an increase in MN-166 related expenses for a MRC-001 PK study and a degenerative cervical myelopathy (DCM) s…
如何读 10-Q 的风险因素(第 1A 项)
10-Q 的风险因素章节有三种常见形态,本页按其一分类展示:
- 指向(pointer) — 公司仅声明"无重大变化"并指向年度 10-K 的完整风险因素;本季没有自己的风险文本可对比。
- 部分更新(partial) — 公司写明"除下述外无重大变化",只更新部分风险;摘录展示的正是本季新增的内容。
- 全文重述(restated) — 本季重新给出完整风险因素。若上一季只是"指向",则无法逐段对比,本页会将其标为"本季全文重述"。
这只是对文件结构的客观描述,不构成对风险高低的判断。
数据来自 SEC EDGAR 两份申报文件的文本级对比 · 确定性计算(无 AI 生成内容)· 仅供参考 · 非投资建议